メンバー

スタッフ

English Information

おおば こうじ

大庭 幸治准教授　　　

OBA Koji

情報学環; 医学系研究科 公共健康医学専攻 生物統計学分野（兼担）

oba [at] epistat.m.u-tokyo.ac.jp

研究

メタアナリシス、代替エンドポイント評価、因果推論、臨床試験デザイン

経歴

2003.03 東京大学医学部健康科学・看護学科卒業
2005.03 東京大学大学院医学系研究科　健康科学･看護学専攻　博士前期課程修了
2005.04 京都大学大学院医学研究科　社会健康医学系専攻　疫学研究情報管理学分野　助手
2006.10 京都大学大学院医学研究科　EBM研究センター　特任助教（2009年10月より、同センター 特定助教）
2010.04 北海道大学　北海道大学病院　高度先進医療支援センター　助教
2011.09 京都大学学位取得(社会健康医学)
2011.12 北海道大学　北海道大学病院　高度先進医療支援センター　データ管理部門　部門長／ 講師
　　　 （2012年10月ー2013年10月　キュリー研究所（フランス）、ハッセルト大学（ベルギー） 客員研究員）
2014.07 東京大学大学院医学系研究科 公共健康医学専攻　生物統計学分野　准教授
2014.08 東京大学大学院　情報学環　准教授 (配置換)
　　　 東京大学大学院医学系研究科 公共健康医学専攻　生物統計学分野　准教授（兼担）
2018.04 東京大学大学院　情報学環・学際情報学府　生物統計情報学コース　コース長
　　　 東京大学大学院　情報学環　准教授 (配置換)
　　　 東京大学大学院医学系研究科 公共健康医学専攻　生物統計学分野　准教授（兼担）
2021.12 東京大学大学院　情報学環・学際情報学府　生物統計情報学コース　コース長
　　　 東京大学大学院　情報学環　准教授 (配置換)
　　　 東京大学大学院医学系研究科 公共健康医学専攻　生物統計学分野　准教授（兼担）
　　　 高知大学　客員教授

東京大学卓越研究員（2016-17年度）
日本計量生物学会試験統計家認定制度　責任試験統計家（2018年度-）
オンライン授業等におけるグッドプラクティス総長表彰（2020年度）

活動

日本計量生物学会（2015- 評議員、2021- 理事）╱　国際計量生物学会╱　日本臨床試験学会╱　日本癌治療学会╱　International Society for Clinical Biostatistics (ISCB) ╱　Society for Clinical Trials (SCT)

現在、進行再発胃がん／術後胃がんを対象とした臨床試験の個人データに基づくメタアナリシスプロジェクト（GASTRIC project）を実施しています。詳細は下記をご覧ください。https://gastricproject.org/

  1. Watanabe J, Kagawa Y, Chida K, et al. Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial. ESMO Gastrointestinal Oncology. 2023;1:9-14.
  2. Fukuda M, Sakamaki K, Oba K. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching. Clin Trials. 2023 Jul 16:17407745231186081. doi: 10.1177/17407745231186081
  3. Fukuhara H, Hagiwara Y, Oba K, Inoue K. Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): cost impact of transurethral resection of bladder tumor in Japan. Photodiagnosis Photodyn Ther. 2023;103758. doi: 10.1016/j.pdpdt.2023.103758.
  4. Mayanagi S, Oba K, Aoyama T, Tanaka K, Kanda M, Honda M, Maeda H, Kashiwabara K, Muto M, Sakamoto J, Yamagishi H, Yoshikawa T. Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials. Anticancer Res. 2023 Jul;43(7):3089-3095. doi: 10.21873/anticanres.16480
  5. Sankoda A, Nagae Y, Waki K, Sze WT, Oba K, Mieno M, Nangaku M, Yamauchi T, Ohe K. Glycemic control, renal progression, and usage of telemedicine phone consultations among Japanese type 2 diabetes mellitus patients during the COVID-19 pandemic: a retrospective cohort study. JMIR Diabetes. 2023 May 24. doi: 10.2196/42607
  6. Tsubono K, Oba K, Fudetani Y, Ikeda C, Sakamoto J. Multidimensional analysis of schoolteachers' occupational stress by the New Brief Job Stress Questionnaire: focusing on gender differences. Ind Health. 2023 May 26. doi: 10.2486/indhealth.2023-0018
  7. Abe S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Yokoyama Y, Matsuzaki H, Nagai Y, Yoshioka Y, Shinagawa T, Sonoda H, Yamamoto Y, Oba K, Ishihara S. Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial. BMC Cancer. 2023 May 17;23(1):450. doi: 10.1186/s12885-023-10941-z
  8. Aoyama T, Oba K, Honda M, Muto M, Mayanagi S, Maeda H, Kanda M, Kashiwabara K, Sakamoto J, Yoshikawa T. The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival. Int J Clin Oncol. 2023 Jun;28(6):777-784. doi: 10.1007/s10147-023-02332-y
  9. Fuyama K, Ogawa M, Mizusawa J, Kanemitsu Y, Fujita S, Kawahara T, Sakamaki K, Oba K. Impact of correlations between prioritized outcomes on the net benefit and its estimate by generalized pairwise comparisons. Stat Med. 2023 May 10;42(10):1606-1624. doi: 10.1002/sim.9690.
  10. Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, Onizuka M, Yokose N, Fujimaki K, Hagihara M, Oshikawa G, Murayama K, Kumagai T, Kimura S, Najima Y, Iriyama N, Tsutsumi I, Oba K, Kojima H, Sakamaki H, Inokuchi K; Kanto CML Study Group. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study. Int J Hematol. 2023 May;117(5):694-705. doi: 10.1007/s12185-023-03549-3.
  11. Yamashina A, Nishikori M, Fujimito H, Oba K. Identification of predictive factors interacting with heart rate reduction for potential beneficial clinical outcomes in chronic heart failure: A systematic literature review and meta-analysis. Int J Cardiol Heart Vasc 2022;43:101141.
  12. Noguchi T, Ishihara S, Uchino M, Ikeuchi H, Okabayashi K, Futami K, Tanaka S, Ohge H, Nagahara H, Watanabe K, Itabashi M, Okamoto K, Okita Y, Mizushima T, Mizuuchi Y, Yamada K, Shimada Y, Sato Y, Kimura H, Takahashi K, Hida K, Kinugasa Y, Okuda J, Daito K, Koyama F, Ueno H, Yamamoto T, Hanai T, Maemoto A, Oba K, Ajioka Y, Sugihara K; Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by the Japanese Society for Cancer of the Colon, Rectum. Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn's disease. J Gastroenterol 2023;58(1):14-24.
  13. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Okiyama N, Kodera M, Hasegawa M, Sato S. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2022;4(8): e546 – e555. https://doi.org/10.1016/S2665-9913(22)00131-X
  14. Oba K, Kagiwada Y, Kamada M, Miki R, Kondo Y, Kamakura T, Yamagami T, Fujita T, Tsuchida Y. Evaluating the feasibility of a remote-based training program supported by information and communications technology in the older adults living at home. BMC Geriatr. 2022;22(1):574. doi: 10.1186/s12877-022-03273-3.
  15. Watanabe J, Maeda H, Nagasaka T, Yokota M, Hirata K, Akazawa N, Kagawa Y, Yamada T, Shiozawa M, Ando T, Kato T, Mishima H, Sakamoto J, Oba K, Nagata N. Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. Int J Cancer. 2022 Dec 15;151(12):2172-2181. doi: 10.1002/ijc.34184.
  16. Nagata H, Kawai K, Oba K, Nozawa H, Yamauchi S, Sugihara K, Ishihara S. Laparoscopic Colectomy: A Risk Factor for Postoperative Peritoneal Metastasis. Clin Colorectal Cancer. 2022 Sep;21(3):e205-e212. doi: 10.1016/j.clcc.2022.05.003.
  17. Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Nakamura M, Nakamura M, Okuda H, Iwanaga I, Kato T, Nakano S, Sato A, Harada K, Oba K, Sakata Y, Sakamoto N, Komatsu Y. Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201). Oncologist. 2022;27: 340–e374.
  18. Kemmochi M, Nawa Y, Ohno S, Sawashita Y, Terada H, Oba K. Analysis of the radial and ulnar arteries using ultrasound and a vascular visualization device in children. Paediatr Anaesth 2022;32(6):747-753. doi: 10.1111/pan.14434.
  19. Sawamoto R, Oba K, Matsuyama Y. Bayesian adaptive randomization design incorporating propensity score-matched historical controls. Pharm Stat. 2022 Sep;21(5):1074-1089. doi: 10.1002/pst.2203.
  20. Ebata S, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Yoshihide A, Yoshizaki A, Sato S. Predictors of Rituximab Effect on Modified Rodnan Skin Score in Systemic Sclerosis: a machine learning analysis of the DESIRES trial. Rheumatology (Oxford). 2022 Nov 2;61(11):4364-4373. doi: 10.1093/rheumatology/keac023.
  21. Ishigami H, Tsuji Y, Shinohara H, Kodera Y, Kanda M, Yabusaki H, Ito S, Imano M, Yamashita H, Hidemura A, Yamaguchi H, Fukagawa T, Oba K, Kitayama J, Seto Y. Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial. J Clin Med. 2021 Nov 30;10(23):5666. doi: 10.3390/jcm10235666.
  22. Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S. Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study. Diagnostics (Basel). 2021 Dec 4;11(12):2274. doi: 10.3390/diagnostics11122274.
  23. Ito C, Hashimoto A, Uemura K, Oba K. Misleading Reporting (Spin) in Noninferiority Randomized Clinical Trials in Oncology With Statistically Not Significant Results: A Systematic Review. JAMA Netw Open. 2021 Dec 1;4(12):e2135765. doi: 10.1001/jamanetworkopen.2021.35765.
  24. Miyo M, Kato T, Nakamura Y, Taniguchi H, Takahashi Y, Ishii M, Okita K, Ando K, Yukami H, Mishima S, Yamazaki K, Kotaka M, Watanabe J, Oba K, Aleshin A, Billings PR, Rabinowitz M, Kotani D, Oki E, Takemasa I, Mori M, Yoshino T. DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. Cancer Sci. 2022 Apr;113(4):1531-1534. doi: 10.1111/cas.15226.
  25. Abe S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Kishikawa J, Ishii H, Yokoyama Y, Nagai Y, Anzai H, Sonoda H, Oba K, Ishihara S. Preoperative sarcopenia is a poor prognostic factor in lower rectal cancer patients undergoing neoadjuvant chemoradiotherapy: a retrospective study. Int J Clin Oncol. 2022 Jan;27(1):141-153. doi: 10.1007/s10147-021-02062-z.
  26. Machida H, Matsuo K, Oba K, Aoki D, Enomoto T, Okamoto A, Katabuchi H, Nagase S, Mandai M, Yaegashi N, Yamagami W, Mikami M. Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study. J Gynecol Oncol. 2022 Jan;33(1):e3. doi: 10.3802/jgo.2022.33.e3.
  27. Hojo D, Murono K, Nozawa H, Kawai K, Hata K, Tanaka T, Oba K, Ishihara S. Improvement in Surgical Outcomes Using 3D Printed Models for Lateral Pelvic Lymph Node Dissection in Rectal Cancer. Dis Colon Rectum. 2022 Apr 1;65(4):566-573. doi: 10.1097/DCR.0000000000002327.
  28. Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. J Dermatol. 2022 Jan;49(1):179-183. doi: 10.1111/1346-8138.16206.
  29. Ota K, Oba K, Ito Y, Cheng J, Ota K, Takasu A. Focused Assessment with Sonography for Trauma (FAST) training for first-year resident physicians at a university hospital in Japan: A longitudinal, observational study. SAGE Open Medicine. 2021;9: 20503121211044367.
  30. Furihata R, Kuwabara M, Oba K, Watanabe K, Takano N, Nagamine N, Maruyama Y, Ito N, Watanabe I, Tsubono K, Ikeda C, Sakamoto J. Association between working overtime and psychological stress reactions in elementary and junior high school teachers in Japan: A large-scale cross-sectional study. Ind Health. 2022 Apr 1;60(2):133-145.
  31. Aizawa H, Kato H, Oba K, Kawahara T, Okubo Y, Saito T, Naito M, Urushitani M, Tamaoka A, Nakamagoe K, Ishii K, Kanda T, Katsuno M, Atsuta N, Maeda Y, Nagai M, Nishiyama K, Ishiura H, Toda T, Kawata A, Abe K, Yabe I, Takahashi-Iwata I, Sasaki H, Warita H, Aoki M, Sobue G, Mizusawa H, Matsuyama Y, Haga T, Kwak S. Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J Neurol. 2022 Feb;269(2):885-896. doi: 10.1007/s00415-021-10670-y.
  32. Chamseddine AN, Oba K, Buyse M, Boku N, Bouché O, Satar T, Auperin A, Paoletti X. Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer. Contemp Clin Trials. 2021 Jun:105:106400. doi: 10.1016/j.cct.2021.106400.
  33. Kato T, Kagawa Y, Kuboki Y, Gamoh M, Komatsu Y, Yasui H, Satake H, Oki E, Tanioka H, Kotaka M, Makiyama A, Denda T, Goto M, Yoshino T, Yamazaki K, Soeda J, Shibuya K, Iwata M, Oba K, Yamaguchi K. Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. Int J Clin Oncol. 2021 Jul;26(7):1238-1247. doi: 10.1007/s10147-021-01902-2.
  34. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Asano Y, Okiyama N, Kodera M, Hasegawa M, Sato S. Safety and efficacy of rituximab in systemic sclerosis: a double-blind, parallel-group comparison, investigators initiated confirmatory clinical trial (DESIRES). Lancet Rheumatol. 2021; 3(7): E489-E497. https://doi.org/10.1016/S2665-9913(21)00107-7
  35. Kuwabara M, Oba K, Takano N, Nagamine N, Maruyama Y, Ito N, Watanabe I, Ikeda C, Sakamoto J. An exploratory questionnaire survey about overwork on mental health of Japanese elementary and junior high school teachers. J Ment Health Train Educ Pract 2021. https://doi.org/10.1108/JMHTEP-01-2020-0002
  36. Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, Nakamura M, Ojima H, Kagawa Y, Matsuhashi N, Okuda H, Asayama M, Yuasa Y, Shimada Y, Manaka D, Watanabe J, Oba K, Yoshino T, Yoshida K, Maehara Y. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open. 2021;6: 100093.
  37. Shimada H, Fukagawa T, Haga Y, Okazumi S, Oba K. Clinical TNM staging for esophageal, gastric, and colorectal cancers in the era of neoadjuvant therapy: A systematic review of the literature. Ann Gastroenterol Surg. 2021 Jul; 5(4): 404–418.
  38. Ota K, Oba K, Fukui K, Ito Y, Hamada E, Mori N, Oka M, Ota K, Shibata Y, Takasu A. Sites of blood collection and topical antiseptics associated with contaminated cultures: prospective observational study. Sci Rep. 2021 Mar 18;11(1):6211.
  39. Kuzumi A, Yoshizaki A, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S. Serum TARC Levels in Patients with Systemic Sclerosis: Clinical Association with Interstitial Lung Disease. J Clin Med. 2021 Feb 9;10(4):660.
  40. Ishibashi K, Aoyama T, Kotaka M, Satake H, Tsuji Y, Kataoka M, Nakamura M, Nagata N, Sakamoto J, Oba K, Mishima H. Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study). Cancer Chemother Pharmacol. 2021 May;87(5):665-672.
  41. Kotani H, Yoshizaki A, Matsuda KM, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S. Serum Calponin 3 Levels in Patients with Systemic Sclerosis: Possible Association with Skin Sclerosis and Arthralgia. J Clin Med. 2021 Jan 14;10(2):280.
  42. Norimatsu Y, Yoshizaki Y, Fukasawa T, Ebata S, Oba K, Sato S. COVID-19 pandemic highlighted the importance of telemedicine in the collagen disease of systemic sclerosis (Letters to the Editors). Clin Exp Rheumatol 2020.
  43. Yamada G, Hagiwara Y, Kimura T, Takeuchi Y, Oba K, Masuda K, Matsuyama Y. Impact of body weight gain on the incidence of non-alcoholic fatty liver disease in non-obese Japanese individuals. Am J Gastroenterol. 2021; 116(4): 733-740.
  44. Noma H, Gosho M, Ishii R, Oba K, Furukawa TA. Outlier detection and influence diagnostics in network meta-analysis. Res Synth Methods. 2020 Nov;11(6):891-902. doi: 10.1002/jrsm.1455.
  45. Kobayashi Y, Suzuki R, Yasukawa K, Oba K, Yamauchi T, Yatomi Y, Kadowaki T. Oxidized albumin in blood reflects the severity of multiple vascular complications in diabetes mellitus. Metabol Open. 2020 Mar 14;6:100032. doi: 10.1016/j.metop.2020.100032.
  46. Matsuda KM, Yoshizaki A, Kotani H, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S. Serum heat shock protein 27 levels in patients with systemic sclerosis: a possible biomarker of skin sclerosis. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):e157-e159. doi: 10.1111/jdv.16885.
  47. Shiraishi H, Yamada K, Egawa K, Ishige M, Ochi F, Watanabe A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Kobayashi K, Miyakoshi T, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N. Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency. Brain Dev. 2021 Feb;43(2):214-219. doi: 10.1016/j.braindev.2020.07.019.
  48. Nakanishi R, Akiyoshi T, Toda S, Murakami Y, Taguchi S, Oba K, Hanaoka Y, Nagasaki T, Yamaguchi T, Konishi T, Matoba S, Ueno M, Fukunaga Y, Kuroyanagi H. Radiomics Approach Outperforms Diameter Criteria for Predicting Pathological Lateral Lymph Node Metastasis After Neoadjuvant (Chemo)Radiotherapy in Advanced Low Rectal Cancer. Ann Surg Oncol. 2020 Oct;27(11):4273-4283. doi: 10.1245/s10434-020-08974-w.
  49. Sasaki S, Nagasaki T, Oba K, Akiyoshi T, Mukai T, Yamaguchi T, Fukunaga Y, Fujimoto Y. Risk factors for outlet obstruction after laparoscopic surgery and diverting ileostomy for rectal cancer. Surg Today. 2021 Mar;51(3):366-373. doi: 10.1007/s00595-020-02096-2.
  50. Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer. 2020 Jul 23;20(1):687. doi: 10.1186/s12885-020-07186-5.
  51. Fukayama M, Yoshizaki A, Fukasawa T, Ebata S, Kuzumi A, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S. Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis. J Dermatol. 2020 Nov;47(11):1287-1292. doi: 10.1111/1346-8138.15508.
  52. Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Kii A, Terazawa T, Makiyama A, Takano N, Yokota M, Okita Y, Matoba K, Hasegawa H, Tsuji A, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Oki E, Nagata N, Sakamoto J. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS study). Oncologist. 2020 Dec;25(12):e1855-e1863. doi: 10.1634/theoncologist.2020-0643.
  53. Miyasato Y, Oba K, Yasuno S, Matsuyama Y, Masuda I. Associations between visceral obesity and renal impairment in health checkup participants: a retrospective cohort study. Clin Exp Nephrol. 2020 Oct;24(10):935-945. doi: 10.1007/s10157-020-01921-9.
  54. Motoki H, Masuda I, Yasuno S, Oba K, Shoin W, Usami S, Saito Y, Waki M, Komatsu M, Ueshima K, Nakagawa Y, Son C, Yonemitsu S, Hiramitsu S, Konda M, Onishi K, Kuwahara K. Rationale and design of the EMPYREAN study. ESC Heart Fail. 2020 Oct;7(5):3134-3141. doi: 10.1002/ehf2.12825.
  55. Ikeda T, Kato A, Bougaki M, Araki Y, Ohata T, Kawashima S, Imai Y, Ninagawa J, Oba K, Chang K, Uchida K, Yamada Y. A retrospective review of 10-year trends in general anesthesia for cesarean delivery at a university hospital: the impact of a newly launched team on obstetric anesthesia practice. BMC Health Serv Res. 2020 May 13;20(1):421.
  56. Ebata S, Yoshizaki A, Fukasawa T, Asano Y, Oba K, Sato S. Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. J Dermatol. 2020 Jul;47(7):796-800. doi: 10.1111/1346-8138.15379.
  57. Furihata K, Tsuchikawa M, Miwa T, Naito Y, Oba K, Sakagami M. Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data. Nutrients. 2020 Apr 17;12(4):E1128. doi: 10.3390/nu12041128.
  58. Kozuma K, Kozuma K, Shinozaki T, Kashiwabara K, Oba K; Xience P. M. S. Group; PROMUS Element/Element Plus P. M. S. Group, Matsuyama Y. Multivariable Prediction Model to Estimate the Probability of Restenosis at Proximal Edge After 2nd-generation Drug-Eluting-Stent Implantation: Development and Internal Validation Using a Quantitative Coronary Angiography From the Post-Marketing Surveillance Studies of Everolimus-Eluting Stent in Japan. Cardiovasc Interv Ther. 2020 Apr 18.
  59. Kumazu Y, Oba K, Hayashi T, Yamada T, Hara K, Osakabe H, Shimoda Y, Nakazono M, Nagasawa S, Rino Y, Masuda M, Ogata T, Yoshikawa T, Oshima T. Relationship Between the Waiting Times for Surgery and Survival in Patients with Gastric Cancer. World J Surg. 2020 Apr;44(4):1209-1215.
  60. Fujieda Y, Maeda H, Oba K, Okamoto K, Fukudome I, Shiga M, Kawanishi Y, Akimori T, Kuroiwa H, Nishimoto H, Namikawa T, Murakami I, Kobayashi M, Hanazaki K. Lymph node retrieval after colorectal cancer surgery: a comparative study of the efficacy between the conventional manual method and a new fat dissolution method. Surg Today. 2020 Jan 7.
  61. Tanaka Y, Oba K, Takeuchi T. Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al. Ann Rheum Dis. 2019 Dec 9:annrheumdis-2019-216593.
  62. Yamaguchi H, Takezako N, Ohashi K, Oba K, Kumagai T, Kozai Y, Wakita H, Yamamoto K, Fujita A, Igarashi T, Yoshida C, Ohyashiki K, Okamoto S, Sakamoto J, Sakamaki H, Inokuchi K. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. Int J Hematol. 2020 Mar;111(3):401-408.
  63. Suzuki S, Akiyoshi T, Oba K, Otsuka F, Tominaga T, Nagasaki T, Fukunaga Y, Ueno M. Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory Biomarkers for Patients with Stage II/III Colon Cancer. Ann Surg Oncol. 2020 Mar;27(3):844-852.
  64. Ikeda T, Yamauchi Y, Uchida K, Oba K, Nagase T, Yamada Y. Reference value for expiratory time constant calculated from the maximal expiratory flow-volume curve. BMC Pulm Med. 2019 Nov 11;19(1):208.
  65. Tanaka Y, Oba K, Koike T, Miyasaka N, Mimori T, Takeuchi T, Hirata S, Tanaka E, Yasuoka H, Kaneko Y, Murakami K, Koga T, Nakano K, Amano K, Ushio K, Atumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsunoda S, Dobashi S, Horie N, Sato N. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomized controlled trial. Ann Rheum Dis 2020; 79(1):94-102.
  66. Maeda H, Hazama S, Iwamoto S, Oba K, Tsunedomi R, Okayama N, Suehiro Y, Yamasaki T, Nakagami Y, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials. Oncol Lett. 2019 Nov;18(5):4555-4562.
  67. Hojo D, Murono K, Nozawa H, Kawai K, Hata K, Tanaka T, Oba K, Ishihara S. Utility of a Three-Dimensional Printed Pelvic Model for Lateral Pelvic Lymph Node Dissection Education: A Randomized Controlled Trial. J Am Coll Surg. 2019 Dec;229(6):552-559.
  68. Munemoto Y, Nakamura M, Takahashi M, Kotaka M, Kuroda H, Kato T, Minagawa N, Noura S, Fukunaga M, Kuramochi H, Touyama T, Takahashi T, Miwa K, Satake H, Kurosawa S, Miura T, Mishima H, Sakamoto J, Oba K, Nagata N. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. Eur J Cancer. 2019 Aug 21;119:158-167.
  69. Akiyoshi T, Toda S, Tominaga T, Oba K, Tomizawa K, Hanaoka Y, Nagasaki T, Konishi T, Matoba S, Fukunaga Y, Ueno M, Kuroyanagi H. Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer. BJS Open. 2019;3(6):822–829.
  70. Shiraishi H, Yamada K, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Miyakoshi T, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey. Mol Genet Metab Rep. 2019;20:100496.
  71. Trotta L, Kabeya Y, Buyse M, Doffagne E, Venet D, Desmet L, Burzykowski T, Tsuburaya A, Yoshida K, Miyashita Y, Morita S, Sakamoto J, Praveen P, Oba K. Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. Clin Trials. 2019 Jul 23:1740774519862564.
  72. Tominaga T, Akiyoshi T, Yamamoto N, Oba K, Nagasaki T, Yamaguchi T, Konishi T, Fukunaga Y, Ueno M. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Surgery. 2019 Jul 22.
  73. Shinagawa T, Hata K, Ikeuchi H, Fukushima K, Futami K, Sugita A, Uchino M, Watanabe K, Higashi D, Kimura H, Araki T, Mizushima T, Itabashi M, Ueda T, Koganei K, Oba K, Ishihara S, Suzuki Y. Clin Gastroenterol Hepatol. 2019 Jul 20.
  74. Nagata H, Ishihara S, Oba K, Tanaka T, Hata K, Kawai K, Nozawa H. Development and Validation of a Prediction Model for Organ-Specific Recurrences After Curative Resection of Colon Cancer. Dis Colon Rectum. 2019 Jul 12.
  75. Sugiyama T, Oba K, Kobayashi Y. Risk-Stratified Incidence of Renal Replacement Therapy Initiation: A Longitudinal Analysis Using Medical Claims and Health Checkup Data. Tohoku J Exp Med. 2019 Jun;248(2):125-135.
  76. Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S, Komatsu Y, Celio L, Aapro M. One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. Oncologist. 2019 Jun 19. pii: theoncologist.2019-0133. doi: 10.1634/theoncologist.2019-0133.
  77. Akiyoshi T, Tanaka N, Kiyotani K, Gotoh O, Yamamoto N, Oba K, Fukunaga Y, Ueno M, Mori S. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019 Jun 13. doi: 10.1002/bjs.11179.
  78. Kozuma Kayoko, Shinozaki T, Kozuma Ken, Kashiwabara K, Oba K, Aoki J, Awata M, Nanasato M, Shiode N, Tanabe K, Yamaguchi J, Kimura T, Matsuyama Y. Impact of residual stenosis on the angiographic edge restenosis of second-generation drug-eluting stent -integrated analysis of quantitative coronary angiography from four post-marketing surveillances of cobalt-chromium everolimus-eluting stent in Japan-. Int Heart J. 2019, in press.
  79. Ota K, Fukui K, Oba K, Shimoda A, Oka M, Ota K, Sakaue M, Takasu A. The role of ultrasound imaging in adult patients with testicular torsion: a systematic review and meta-analysis. J Med Ultrason (2001). 2019 Mar 7. doi: 10.1007/s10396-019-00937-3.
  80. Tanioka H, Honda M, Tanaka C, Morita Y, Ishibashi K, Kato T, Matsuda C, Kataoka M, Satake H, Munemoto Y, Kobayashi K, Takahashi M, Nakata K, Sakamoto J, Oba K, Mishima H. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety. Int J Clin Oncol. Int J Clin Oncol. 2019 Feb 18. doi: 10.1007/s10147-019-01414-0.
  81. Kobayashi S, Kishi R, Saijo Y, Ito Y, Oba K, Araki A, Miyashita C, Itoh S, Minatoya M, Yamazaki K, Ait Bamai Y, Sato T, Yamazaki S, Nakayama SF, Isobe T, Nitta H; Japan Environment and Children's Study Group. Association of blood mercury levels during pregnancy with infant birth size by blood selenium levels in the Japan Environment and Children's Study: A prospective birth cohort. Environ Int. 2019 Apr;125:418-429.
  82. Maeda H, Nagata N, Nagasaka T, Oba K, Mishima H, Kato T, Yoshida K, Muro K, Sakamoto J. A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study. Oncol Lett. 2019 Feb;17(2):1980-1985.
  83. Iwamoto S, Maeda H, Hazama S, Oba K, Okayama N, Suehiro Y, Yamasaki T, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer. J Cancer. 2018 Oct 18;9(22):4092-4098.
  84. Fujieda Y, Maeda H, Oba K, Okamoto K, Shiga M, Fujisawa K, Yokota K, Namikawa T, Kobayashi M, Hanazaki K. Factors influencing the number of retrieved lymph nodes after colorectal resection: a retrospective study from a single institute. Int J Clin Exp Pathol 2018;11(3):1694-1700
  85. Shimada H, Fukagawa T, Haga Y, Oba K. Does postoperative morbidity worsen the oncological outcome after radical surgery for gastrointestinal cancers? A systematic review of the literature. Ann Gastroenterol Surg. 2017 Apr 25;1(1):11-23.
  86. Liu J, Yasuno S, Oba K, Konda M, Ichihara C, Kitao H, Kuwabara Y, Ueshima K. Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. J Hypertens. 2018 Sep;36(9):1921-1928.
  87. Kondo T, Fujioka M, Tsuda M, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Nagashima T, Wakasa K, Fujimoto N, Yamamoto S, Yonezumi M, Saito S, Sato S, Ogawa K, Chou T, Watanabe R, Kato Y, Takahashi S, Okano Y, Yamamoto J, Ohta M, Iijima H, Oba K, Kishino S, Sakamoto J, Ishida Y, Ohba Y, Teshima T; Inter-Michinoku Dasatinib Study Group (IMIDAS). Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib. Cancer Sci. 2018 Jul;109(7):2256-2265.
  88. Matsuda C, Honda M, Tanaka C, Kondo K, Takahashi T, Kosugi C, Tokunaga Y, Takemoto H, Kim HM, Sakamoto J, Oba K, Mishima H. A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. Cancer Chemother Pharmacol. 2018 Jun;81(6):1035-1041.
  89. Yamada K, Shiraishi H, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Miyakoshi T, Ono K, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan. Mol Genet Metab Rep 2018;15:55-63.
  90. Kubota T, Nakayama H, Kitaoka T, Nakamura Y, Fukumoto S, Fujiwara I, Hasegawa Y, Ihara K, Kitanaka S, Koyama S, Kusuda S, Mizuno H, Nagasaki K, Oba K, Sakamoto Y, Takubo N, Shimizu T, Tanahashi Y, Hasegawa K, Tsukahara H, Yorifuji T, Michigami T, Ozono K. Incidence rate and characteristics of symptomatic vitamin D deficiency in children: a nationwide survey in Japan. Endocr J. 2018 Mar 10.
  91. Nagata H, Ishihara S, Oba K, Tanaka T, Hata K, Kawai K, Nozawa H. Development and Validation of a Prediction Model for Postoperative Peritoneal Metastasis After Curative Resection of Colon Cancer. Ann Surg Oncol. 2018 Mar 5.
  92. Munemoto Y, Kanda M, Oba K, Kim HM, Takemoto H, Denda T, Nagata N, Takano N, Fukunaga M, Kataoka M, Tokunaga Y, Sakamoto J, Mishima H. A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. Cancer Chemother Pharmacol. 2018 Mar 5.
  93. Ishiguro N, Koseki N, Kaiho M, Ariga T, Kikuta H, Oba K, Togashi T, Morita K, Inagawa A, Okamura A, Yamazaki S, Shida S, Konno M, Kawamura N, Ishizaka A, Takada K, Tsubakihara K, Nagano N, Shibata M, Furuyama H, Matsuzono Y, Koike A, Murashita M, Hatae Y, Arioka H, Yamanaka T, Watanabe T, Tabata Y, Kumita Y, Hazama K, Akutsu Y, Aoyagi H, Tobise C, Azuma K, Yasoshima K, Sawada Y, Uetsuji K, Tsuchida A, Tsuchiyama A, Yasuda K, Odagawa Y, Yoshioka M. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan. J Infect Chemother 2018. pii: S1341-321X(18)30032-1.
  94. Namikawa T, Maeda H, Kitagawa H, Oba K, Tsuji A, Yoshikawa T, Kobayashi M, Hanazaki K. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol. BMC Cancer 2018;18:186.
  95. Maeda H, Okamoto K, Oba K, Shiga M, Fujieda Y, Namikawa T, Hiroi M, Murakami I, Hanazaki K, Kobayashi M. Lymph node retrieval after dissolution of surrounding adipose tissue for pathological examination of colorectal cancer. Oncol Lett 2018;15:2495-500.
  96. Kawahara T, Fukuda M, Oba K, Sakamoto J, Buyse M. Meta-analysis of randomized clinical trials in the era of individual patient data sharing. Int J Clin Oncol. 2018 Jan 12.
  97. Yamazaki Y, Oba K, Matsui Y, Morimoto Y. Vasoactive-inotropic score as a predictor of morbidity and mortality in adults after cardiac surgery with cardiopulmonary bypass. J Anesth. 2018 Jan 13.
  98. Ogura A, Akiyoshi T, Yamamoto N, Kawachi H, Ishikawa Y, Mori S, Oba K, Nagino M, Fukunaga Y, Ueno M. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer. Eur J Cancer 2018;91:11-20.
  99. Mayanagi S, Kashiwabara K, Honda M, Oba K, Aoyama T, Kanda M, Maeda H, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T. Risk factors for peritoneal recurrence in stage II-III colon cancer. Dis Colon Rec 2017. Accepted on 10 Aug 2017.
  100. Honda M, Oba K, Akiyoshi T, Maeda H, Kashiwabara K, Kanda M, Mayanagi S, Aoyama T, Hamada C, Sadahiro S, Fukunaga Y, Ueno M, Sakamoto J, Saji S, Yoshikawa T. Development and Validation of a Prognostic Nomogram for Colorectal Cancer after Radical Resection based on individual patient data from three large-scale phase III trials. OncoTarget 2017;8: 99150-99160.
  101. Kanda M, Oba K, Aoyama T, Kashiwabara K, Mayanagi S, Maeda H, Honda M, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T. Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials. Dis Colon Rec 2017. Accepted on 31 Oct 2017.
  102. Kawai K, Nozawa H, Hata K, Tanaka T, Nishikawa T, Oba K, Watanabe T. Optimal interval for 18F-FDG-PET after chemoradiotherapy for rectal cancer. Clin Colorectal Cancer. Available online 21 November 2017
  103. Oba K, Horie N, Sato N, Saito K, Takeuchi T, Mimori T, Miyasaka N, Koike T, Tanaka Y. Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. Contemp Clin Trials Commun 2017;8:49-54.
  104. Maeda H, Okamoto K, Oba K, Kobayashi M. Lymph node retrieval using fat dissolution technique after surgical resection of colorectal cancer: a protocol paper. Ann Can Res Ther 2017; 25: 90-1.
  105. Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, Noguchi M, Koike M, Sakamoto J, Oba K, Komatsu N. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group. Oncology. 2017 Nov 18. doi: 10.1159/000481945. [Epub ahead of print]
  106. Okuno K, Aoyama T, Oba K, Yokoyama N, Matsuhashi N, Kunieda K, Nishimura Y, Akamatsu H, Kobatake T, Morita S, Yoshikawa T, Sakamoto J, Saji S. Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial). Cancer Chemother Pharmacol. 2017 Nov 1. doi: 10.1007/s00280-017-3466-7. [Epub ahead of print]
  107. Maeda H, Kashiwabara K, Aoyama T, Oba K, Honda M, Mayanagi S, Kanda M, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T. Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials. J Cancer 2017; 8(19): 4057–4064.
  108. Murai K, Yamaguchi K, Ito S, Miyagishima T, Shindo M, Wakasa K, Inomata M, Nagashima T, Kondo T, Fujimoto N, Yamamoto S, Yonezumi M, Oyake T, Kowata S, Tsukushi Y, Mine T, Meguro K, Ikeda K, Watanabe R, Saito S, Sato S, Tajima K, Chou T, Kubo K, Oba K, Sakamoto J, Ishida Y; The Inter-Michinoku Dasatinib Study Group (IMIDAS). Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients. Eur J Haematol. 2017 Sep 12. doi: 10.1111/ejh.12969. [Epub ahead of print]
  109. Arakawa K, Kawai K, Ishihara S, Hata K, Nozawa H, Oba K, Sugihara K, Watanabe T. Prognostic Significance of Peritoneal Metastasis in Stage IV Colorectal Cancer Patients With R0 Resection: A Multicenter, Retrospective Study. Dis Colon Rectum 2017;60:1041-1049.
  110. Aoyama T, Kashiwabara K, Oba K, Honda M, Sadahiro S, Hamada C, Maeda H, Mayanagi S, Kanda M, Sakamoto J, Saji S, Yoshikawa T. Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials. Cancer Medicine 2017; 6(11): 2523-2530. Doi: 10.1002/cam4.1126.
  111. Aoyama T, Oba K, Honda M, Sadahiro S, Hamada C, Mayanagi S, Kanda M, Maeda H, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T. Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials. Cancer Med 2017 Jun 22. DOI: 10.1002/cam4.1126
  112. Aoyama T, Sato T, Hayashi T, Yamada T, Cho H, Ogata T, Oba K, Yoshikawa T. Does a laparoscopic approach attenuate the body weight loss and lean body mass loss observed in open distal gastrectomy for gastric cancer? a single-institution exploratory analysis of the JCOG 0912 phase III trial. Gastric Cancer. 2017 Jun 16. doi: 10.1007/s10120-017-0735-4. [Epub ahead of print]
  113. Kusano M, Honda M, Okabayashi K, Akimaru K, Kino S, Tsuji Y, Watanabe M, Suzuki S, Yoshikawa T, Sakamoto J, Oba K, Saji S. Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003. J Cancer Res Ther 2017;13(1):84-90.
  114. Kotake M, Aoyama T, Munemoto Y, Doden K, Kataoka M, Kobayashi K, Nishimura G, Fujita H, Nakamura K, Takehara A, Tanaka C, Sakamoto J, Nagata N, Oba K, Kondo K. Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial). Oncol Lett 2017;13(2):747-753.
  115. Ishiguro N, Koseki N, Kaiho M, Ariga T, Kikuta H, Togashi T, Oba K, Morita K, Nagano N, Nakanishi M, Hara K, Hazama K, Watanabe T, Yamanaka T, Sasaki S, Furuyama H, Shibata M, Shida S, Ishizaka A, Tabata Y, Aoyagi H, Naito H, Yoshioka M, Horino A, Kenri T; Hokkaido Pediatric Respiratory Infection Study Group. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PLoS One 2017;12(3):e0173635.
  116. Nagata N, Mishima H, Kurosawa S, Oba K, Sakamoto J. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale. Clin Colorectal Cancer 2017; 16(2):154-157.e1.
  117. Shiga M, Maeda H, Oba K, Okamoto K, Namikawa T, Fujisawa K, Yokota K, Kobayashi M, Hanazaki K. Safety of laparoscopic surgery for colorectal cancer in patients over 80 years old: a propensity score matching study. Surg Today. 2017 Jan 27. [Epub ahead of print]
  118. Ikeda T, Uchida K, Yamauchi Y, Nagase T, Oba K, Yamada Y. Relationship between pre-anesthetic and intra-anesthetic airway resistance in patients undergoing general anesthesia: A prospective observational study. PLoS One 2017;12(2):e0172421.
  119. Nakamura M, Aoyama T, Ishibashi K, Tsuji A, Takinishi Y, Shindo Y, Sakamoto J, Oba K, Mishima H. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study). Cancer Chemother Pharmacol 2017;79:29-36.
  120. Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C, Fujieda S, Nakata K, Murotani K, Oba K, Sakamoto J, Mishima H. Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemother Pharmacol 2016;78:1253-1261.
  121. Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, Atsumi T, Manda N, Kurihara Y, Aoki S; SAIS Study Group. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PLoS One. 2016 Oct 6;11:e0164255.
  122. Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Ann Surg Oncol. 2016 Sep 8.
  123. Kozuma K, Kashiwabara K, Shinozaki T, Kozuma K, Oba K, Matsuyama Y. Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA). Int J Cardiovasc Imaging. 2017;33(6):779-787. doi: 10.1007/s10554-017-1068-4.
  124. Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T. Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-associated Colorectal Cancer. Gastroenterology. 2016 Aug 11. [Epub ahead of print].
  125. Furihata T, Kinugawa S, Fukushima A, Takada S, Homma T, Masaki Y, Abe T, Yokota T, Oba K, Okita K, Tsutsui H. Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure. Int J Cardiol 2016 ;220:483-7.
  126. Hazama S, Maeda H, Iwamoto S, Kim HM, Takemoto H, Kobayashi K, Sakamoto J, Nagata N, Oba K, Mishima H. A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study). Clin Colorectal Cancer. 2016 Jul 18. [Epub ahead of print]
  127. Matsui T, Nagata N, Hirata K, Okazaki S, Sato S, Nakamura M, Kim H, Oba K, Sakamoto J, Mishima H. Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial. Anticancer Res 2016;36:3437-43.
  128. Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S. A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32). J Cancer Res Ther. 2018 Sep;14(Supplement):S761-S766.
  129. Mabe K, Kato M, Oba K, Nakagawa S, Seki H, Katsuki S, Yamashita K, Ono S, Shimizu Y, Sakamoto N; Sapporo Consensus Study Group. A prospective, multicenter survey on the validity of shorter periendoscopic cessation of antithrombotic agents in Japan. J Gastroenterol. 2016 Apr 16. [Epub ahead of print]
  130. Noguchi K, Sakakibara M, Asakawa N, Tokuda Y, Kamiya K, Yoshitani T, Oba K, Miyauchi K, Nishizaki Y, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y, Kimura K, Origasa H, Isshiki T, Morino Y, Daida H, Tsutsui H; PACIFIC investigators. Higher Hemoglobin A1c After Discharge Is an Independent Predictor of Adverse Outcomes in Patients With Acute Coronary Syndrome　- Findings From the PACIFIC Registry. Circ J 2016;80:1607-14.
  131. Matsumoto M, Kato M, Oba K, Abiko S, Tsuda M, Miyamoto S, Mizushima T, Ono M, Omori S, Takahashi M, Ono S, Mabe K, Nakagawa M, Nakagawa S, Kudo T, Shimizu Y, Sakamoto N. Multicenter randomized controlled study to assess the effect of prophylactic clipping on post-polypectomy delayed bleeding. Dig Endosc. 2016 Mar 28. doi: 10.1111/den.12661.
  132. Kishikawa J, Kazama S, Oba K, Hasegawa K, Anzai H, Harada Y, Abe H, Matsusaka K, Hongo K, Oba M, Yasuda K, Otani K, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Hata K, Kawai K, Nozawa H, Yamaguchi H, Ishihara S, Sunami E, Ushiku T, Kitayama J, Fukayama M, Kokudo N, Watanabe T. CD133 Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer with Synchronous Liver Metastasis. Ann Surg Oncol. 2016 Jan 29. [Epub ahead of print]
  133. Shimada H, Fukagawa T, Haga Y, Oba K. Does remnant gastric cancer really differ from primary gastric cancer? A systematic review of the literature by the Task Force of Japanese Gastric Cancer Association. Gastric Cancer 2016; 19(2):339-49.
  134. Oba K. Statistical challenges for central monitoring in clinical trials: a review. Int J Clin Oncol 2016;21(1):28-37.
  135. Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, Fukunaga M, Takagane A, Otsuji T, Miyake Y, Nagase M, Sakamoto J, Matsuoka M, Oba K, Mishima H. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer 2015;15:786.
  136. Matsuda C, Honda M, Tanaka C, Fukunaga M, Ishibashi K, Munemoto Y, Hata T, Bando H, Oshiro M, Kobayashi M, Tokunaga Y, Fujii A, Nagata N, Oba K, Mishima H. Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). Int J Clin Oncol. 2015 Oct 16. [Epub ahead of print]
  137. Soda H, Maeda H, Hasegawa J, Takahashi T, Hazama S, Fukunaga M, Kono E, Kotaka M, Sakamoto J, Nagata N, Oba K, Mishima H. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. BMC Cancer 2015;15:695.
  138. Asakawa N, Sakakibara M, Noguchi K, Kamiya K, Yamada S, Yoshitani T, Ono K, Oba K, Tsutsui H. Adaptive Servo-Ventilation Has More Favorable Acute Effects on Hemodynamics Than Continuous Positive Airway Pressure in Patients With Heart Failure. Int Heart J 2015;56:527-32.
  139. Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Miyoshi A, Kondo T, Tsuchida K, Atsumi T, Manda N, Kurihara Y, Aoki S; SAIS Study Group. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2). PLoS One. 2015 Aug 18;10(8):e0135854.
  140. Ishiguro N, Koseki N, Kaiho M, Kikuta H, Togashi T, Oba K, Morita K, Nagano N, Nakanishi M, Hazama K, Watanabe T, Sasaki S, Horino A, Kenri T, Ariga T; Hokkaido Pediatric Respiratory Infection Study Group. Regional Differences in Rates of Macrolide-Resistant Mycoplasma pneumoniae in Hokkaido, Japan. Jpn J Infect Dis. 2015 Jul 10. [Epub ahead of print]
  141. Tada N, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, Kitayama J, Oba K, Watanabe T. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol 2015;13:30
  142. Matsushima M, Yabe I, Oba K, Sakushima K, Mito Y, Takei A, Houzen H, Tsuzaka K, Yoshida K, Maruo Y, Sasaki H. Comparison of Different Symptom Assessment Scales for Multiple System Atrophy. Cerebellum. 2015 Jun 21.
  143. Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T. Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). Cancer Chemother Pharmacol 2015;76:75-84.
  144. Abe Y, Kawakami H, Oba K, Hayashi T, Yasuda I, Mukai T, Isayama H, Ishiwatari H, Doi S, Nakashima M, Yamamoto N, Kuwatani M, Mitsuhashi T, Hasegawa T, Hirose Y, Yamada T, Tanaka M, Sakamoto N; Japan EUS-FNA Stylet Study Group. Effect of a stylet on a histological specimen in EUS-guided fine-needle tissue acquisition by using 22-gauge needles: a multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 2015;82:837-844.
  145. Sakuhara Y, Nishio S, Morita K, Abo D, Hasegawa Y, Yuasa N, Mochizuki T, Soyama T, Oba K, Shirato H, Kudo K. Transcatheter Arterial Embolization with Ethanol Injection in Symptomatic Patients with Enlarged Polycystic Kidneys. Radiology 2015:141637.
  146. Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015 Apr 23.
  147. Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y. An open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci 2015;106:891-5.
  148. Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Biom J. 2015 Feb 12. doi: 10.1002/bimj.201400049.
  149. Murai K, Akagi T, Shimosegawa K, Sugawara T, Ishizawa K, Ito S, Murai K, Motegi M, Yokoyama H, Noji H, Tajima K, Kimura J, Chou T, Ogawa K, Harigae H, Kubo K, Oba K, Sakamoto J, Ishida Y. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria. Eur J Haematol. 2015 Feb 19. doi: 10.1111/ejh.12536.
  150. Shinohara N, Obara W, Tatsugami K, Naito S, Kamba T, Takahashi M, Murai S, Abe T, Oba K, Naito S. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci. 2015 Feb 25. doi: 10.1111/cas.12646.
  151. Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 2015;11:617-27.
  152. Fukushima A, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, Matsushima S, Takada S, Kadoguchi T, Oba K, Okita K, Tsutsui H. Serum Brain-Derived Neurotrophic Factor Level Predicts Adverse Clinical Outcomes in Patients with Heart Failure. J Card Fail 2015 Jan 29. doi: 10.1016/j.cardfail.2015.01.003.
  153. Arai Y, Aoyama T, Inaba Y, Okabe H, Ihaya T, Kichikawa K, Ohashi Y, Sakamoto J, Oba K, Saji S. Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study). Asia Pac J Clin Oncol 2015;11:41-8.
  154. Inokuchi K, Kumagai T, Matsuki E, Ohashi K, Shinagawa A, Hatta Y, Takeuchi J, Yoshida C, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Okamoto S, Oba K, Sakamoto J, Sakamaki H. Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase. J Clin Exp Hematop 2014;54:197-204.
  155. Fujita H, Hatanaka Y, Sutoh Y, Suzuki Y, Oba K, Hatanaka KC, Mitsuhashi T, Otsuka N, Fugo K, Kasahara M, Matsuno Y. Immunohistochemical Validation and Expression Profiling of NKG2D Ligands in a Wide Spectrum of Human Epithelial Neoplasms. J Histochem Cytochem 2014 Dec 3.
  156. Eguchi K, Honda M, Kataoka T, Mukouyama T, Tsuneto S, Sakamoto J, Oba K, Saji S. Efficacy of corticosteroids for cancer-related fatigue: A pilot randomized placebo-controlled trial of advanced cancer patients. Palliat Support Care 2014; 2014 Nov 5:1-8.
  157. Sakashita T, Homma A, Hatakeyama H, Mizumachi T, Kano S, Furusawa J, Iizuka S, Hoshino K, Hatanaka K, Oba K, Fukuda S. The potential diagnostic role of the number of ultrasonographic characteristics for patients with thyroid nodules evaluated as Bethesda I-V. Front Oncol 2014; 4:261.
  158. Kuwatani M, Kawakami H, Hayashi T, Eto K, Yamato H, Onodera M, Naruse H, Oba K. Effect of antispasmodic drugs on endoscopic ultrasound/endoscopic ultrasound-guided fine-needle aspiration: A multicenter randomized controlled trial. Endoscopic Ultrasound 2014; 3: 167-73.
  159. Tsunedomi R, Hazama S, Fujita Y, Okayama N, Kanekiyo S, Inoue Y, Yoshino S, Yamasaki T, Suehiro Y, Oba K, Mishima H, Sakamoto J, Hamamoto Y, Oka M. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Clin Oncol 2014; 45: 1381-90.
  160. Kamiya K, Sakakibara M, Asakawa N, Yamada S, Yoshitani T, Iwano H, Komatsu H, Naya M, Chiba S, Yamada S, Manabe O, Kikuchi Y, Oyama-Manabe N, Oba K, Tsutsui H. Cardiac Magnetic Resonance Performs Better in the Detection of Functionally Significant Coronary Artery Stenosis Compared to Single-Photon Emission Computed Tomography and Dobutamine Stress Echocardiography. Circ J 2014; 78:2468-76.
  161. Nitta T, Mitsuhashi T, Hatanaka Y, Miyamoto M, Oba K, Tsuchikawa T, Suzuki Y, Hatanaka KC, Hirano S, Matsuno Y. Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray. Br J Cancer 2014;111:1363-72.
  162. Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 2014;15:886-93
  163. Kono M, Yasuda S, Kato M, Kanetsuka Y, Kurita T, Fujieda Y, Otomo K, Horita T, Oba K, Kondo M, Mukai M, Yanai M, Fukasawa Y, Atsumi T. Long-term outcome in Japanese patients with lupus nephritis. Lupus 2014; 23:1124-32.
  164. Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, Fujieda Y, Oku K, Bohgaki T, Amengual O, Horita T, Atsumi T. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford). 2014 Apr 24.
  165. Nakai Y, Inoue T, Toda H, Toyomaki A, Nakato Y, Nakagawa S, Kitaichi Y, Kameyama R, Hayashishita Y, Wakatsuki Y, Oba K, Tanabe H, Kusumi I. The influence of childhood abuse, adult stressful life events and temperaments on depressive symptoms in the nonclinical general adult population. J Affect Disord 2014; 158: 101-7.
  166. Maeda H, Hazama S, Shavkat A, Okamoto K, Oba K, Sakamoto J, Takahashi K, Oka M, Nakamura D, Tsunedomi R, Okayama N, Mishima H, Kobayashi M. Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations. Mol Diagn Ther 2014; 18: 333-42.
  167. Iwamoto S, Hazama S, Kato T, Miyake Y, Fukunaga M, Matsuda C, Bando H, Sakamoto J, Oba K, Mishima H. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res 2014; 34: 1967-73.
  168. Cho H, Yoshikawa T, Oba MS, Hirabayashi N, Shirai J, Aoyama T, Hayashi T, Yamada T, Oba K, Morita S, Sakamoto J, Tsuburaya A. Matched pair analysis to examine the effects of a planned preoperative exercise program in early gastric cancer patients with metabolic syndrome to reduce operative risk: The adjuvant exercise for general elective surgery (AEGES) study group. Ann Surg Oncol 2014; 21: 2044-50.
  169. Kumagai T, Matsuki E, Inokuchi K, Ohashi K, Shinagawa A, Takeuchi J, Yoshida C, Okamoto S, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Nishiwaki K, Oba K, Sakamoto J, Sakamaki H. Relative increase in lymphocytes from as early as one month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol 2014; 99: 41-52.
  170. Fukudome I, Kobayashi M, Dabanaka K, Maeda H, Okamoto K, Okabayashi T, Baba R, Kumagai N, Oba K, Fujita M, Hanazaki K. Diamine oxidase as a marker of intestinal mucosal injury and the effect of soluble dietary fiber on gastrointestinal tract toxicity after intravenous 5-fluorouracil treatment in rats. Med Mol Morphol 2014;47:100-7.
  171. Koseki N, Kaiho M, Kikuta H, Oba K, Togashi T, Ariga T, Ishiguro N. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. Influenza and Other Respiratory Viruses 2014;8:151-8
  172. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014;17:26-33
  173. Sasaki H, Matsushima M, Hama Y, Sakushima K, Nakamura M, Yabe I, Oba K, Tanji K, Mori F, Wakabayashi K, Kakita A, Takahashi H, Utsumi J. Plasma matrix metalloproteinase-3 correlates with the clinical severity in men with multiple system atrophy. Neurology and Clinical Neuroscience 2013;1:69-77.
  174. Hirata K, Nagata N, Kato T, Okuyama Y, Ando H, Takahashi K, Oba K, Sakamoto J, Hazama S, Mishima H. Prospective Phase II Trial of Second-line FOLFIRI in Patients with Advanced Colorectal Cancer Including Analysis of UGT1A1 Polymorphisms -A FLIGHT-2 study-. Anticancer Res 2013; 104:1662-9.
  175. Tanaka J, Morishima Y, Takahashi Y, Yabe T, Oba K, Takahashi S, Taniguchi S, Ogawa H, Onishi Y, Miyamura K, Kanamori H, Aotsuka N, Kato K, Kato S, Atsuta Y, Kanda Y. Effects of KIR-ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer Journal 2013; 3:e164.
  176. Oba K, Paoletti X, Alberts S, Bang Y, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent DJ, Shitara K, Van Cutsem E, Buyse M, Burzykowski T. Disease Free Survival as a surrogate for Overall Survival in adjuvant trials of gastric cancer: A meta-analysis. J Natl Cancer Inst 2013; 105: 1600-7.
  177. Paoletti X, Oba K, Bang Y, Bleiberg H, Boku N, Bouche O, Catalano P, Fuse N, Michiels S, Moehler M, Morita S, Ohashi Y, Ohtsu A, Roth A, Rougier P, Sakamoto J, Sargent DJ, Sasako M, Shitara K, Thuss-Patience P, Van Cutsem E, Burzykowski T, Buyse M. Progression-Free Survival As A Surrogate For Overall Survival In Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. J Natl Cancer Inst 2013; 105: 1667-70.
  178. Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated mCRC in two prospective studies in Japan. Cancer Sci 2013; 104:1662-9.
  179. Fukushima A, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, Matsushima S, Abe T, Suga T, Takada S, Kadoguchi T, Katsuyama R, Oba K, Okita K, Tsutsui H. Decreased serum brain-derived neurotrophic factor levels are correlated with exercise intolerance in patients with heart failure. Int J Cardiol 2013;168:e142-4.
  180. Mitsui N, Asakura S, Shimizu Y, Fujii Y, Kako Y, Tanaka T, Oba K, Inoue T, Kusumi I. Temperament and character profiles of Japanese university students with depressive episodes and ideas of suicide or self-harm: A PHQ-9 screening study. Compr Psychiatry 2013; 54: 1215-21.
  181. Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, Nakamae H, Minagawa K, Miyamura K, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishimoto N, Oba K, Masauzi N. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow Transplant 2013;48:1389-94.
  182. Shinohara N, Maruyama S, Shimizu S, Nishioka K, Abe T, C-Hatanaka K, Oba K, Nonomura K, Shirato H. Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer. J Radiat Res 2013; 54: 1095-101.
  183. Osawa T, Shinohara N, Maruyama S, Oba K, Abe T, Maru S, Takada N, Sazawa A, Nonomura K. Long-term renal function outcomes in bladder cancer after radical cystectomy. Urol J 2013;10:784-9.
  184. Tsuburaya A, Nagata N, Cho H, Hirabayashi N, Kobayashi M, Kojima H, Munakata Y, Fukushima R, Kameda Y, Shimoda T, Oba K, Sakamoto J. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol 2013; 71: 1309-14.
  185. Osawa T, Harada H, Oba K, Seki T, Togashi M. Clinical factor affecting the recovery of kidney function in clinically localized renal cell carcinoma patients who underwent nephron-sparing surgery. Hokkaido Igaku Zasshi 2013;88:15-20.
  186. Yamada S, Sakakibara M, Yokota T, Kamiya K, Asakawa N, Iwano H, Yamada S, Oba K, Tsutsui H. Acute hemodynamic effects of adaptive servo-ventilation in patients with heart failure. Circ J 2013;77:1214-20.
  187. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group; Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Tsuburaya A, Van Cutsem E, Buyse M. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 2013;49:1565-77.
  188. Taguchi T, Yamamoto D, Masuda N, Oba K, Nakayama T, Nagata T, Nomura M, Yoshidome K, Yoshino H, Matsunami N, Miyashita M, Furuya Y, Ishida T, Wakita K, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609. Cancer Chemother Pharmacol 2013 ;71:741-7.
  189. Kato T, Ishikawa K, Aragaki M, Sato M, Okamoto K, Ishibashi T, Oba K, Kaji M. Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: differences according to histology and smoking status. J Surg Oncol 2013;107:619-24.
  190. Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, Kudo M, Kato K, Miyagishima T, Uebayashi M, Meguro T, Oba K, Asaka M. Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. Chemotherap 2012;58:439-44.
  191. Kobayashi M, Hazama S, Takahashi K, Oba K, Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, Nakamura D, Sakamoto J, Mishima H. Is there diversity among UGT1A1 polymorphism in Japan? World J Gastrointest Oncol 2012;4:170–5.
  192. Sakakibara M, Yamada S, Kamiya K, Yokota T, Oba K, Tsutsui H. Sleep-Disordered Breathing Is an Independent Risk Factor of Aborted Sudden Cardiac Arrest in Patients With Coronary Artery Spasm. Circ J 2012;76:2204-10.
  193. Iwami D, Harada H, Morita K, Oba K, Fukuzawa N, Hotta K, Sasaki H, Miyazaki C, Nonomura K. Preservation of Deep Inferior Epigastric Artery at Kidney Transplantation Prevents Atrophy of Lower Rectus Abdominis Muscle. Transplantation. 2012;93:1013-6.
  194. Shinohara N, Nonomura K, Abe T, Maruyama S, Kamai T, Takahashi M, Tatsugami K, Yokoi S, Deguchi T, Kanayama H, Oba K, Naito S. A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. Cancer Sci 2012;103:1695-700.
  195. Sakamoto J, Oba K. Geographic difference in advanced gastric cancer prevalence and chemotherapy treatment results: could it really be an independent prognostic factor? Gastric Cancer. 2012;15:232-4.
  196. Shinohara N, Abe T, Mochizuki T, Kashiwagi A, Kanagawa K, Maruyama S, Sazawa A, Oba K, Nonomura K. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol 2011; 31: 1276-82.
  197. Ogihara T, Nakao K, Ueshima K, Oba K, Yasuno S, Fujimoto A, Matsuoka H, Saruta T, on behalf of the CASE-J Ex Study Group. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertens Res 2011;34:1295-301.
  198. Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. Bevacizumab-containing therapy (5 mg/kg or 10 mg/kg) and FOLFIRI in advanced colorectal cancer failed to bevacizumab plus oxaliplatin-based therapy: A Phase III Study (EAGLE Study). Jpn J Clin Oncol 2011;42(2):134-8.
  199. Ueshima K, Oba K, Yasuno S, Fujimoto A, Tanaka S, Ogihara T, Saruta T, Nakao K. Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients: primary and secondary prevention of ischemic heart disease in a subanalysis of the CASE-J (Candesartan Antihypertensive Survival Evaluation in Japan) trial. Circ J 2011; 75: 2411-6.
  200. Nishimura R, Nakamura S, Oba K, Komoike Y, Mitsuyama S, Hisamatsu K, Oriuchi N, Abe C, Kuwayama T, Taguchi T, Sakamoto J, Noguchi S. Prospective study on the effect of toremifene in patients with adjuvant anastrozole failure in postmenopausal breast cancer. Ann Cancer Res Ther 2011; 1: 9-14.
  201. Hara T, Nishikawa K, Sakatoku M, Oba K, Sakamoto J, Omura K. Phase II study of weekly paclitaxel, cisplatin and 5-fluorouracil for advanced gastric cancer. Gastric Cancer 2011; 14: 332-8.
  202. Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J, Mishima H. Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms. Jpn J Clin Oncol 2011;41: 477-82.
  203. Oba K, Sato T, Ogihara T, Saruta T, Nakao K. How to use marginal structural models in randomized trials to estimate the natural direct and indirect effects of therapies mediated by causal intermediates. Clin Trials 2011; 8: 277-87.
  204. Imamoto H, Oba K, Sakamoto J, Iishi H, Narahara H, Yumiba T, Morimoto T, Nakamura M, Oriuchi N, Kakutani C, Morita S, Shiozaki H. Assessing Clinical Benefit Response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer 2011; 14: 81-90.
  205. Oba K, Matsuoka M, Satoh T, Muro K, Oriuchi N, Sakamoto J, Mishima H. Multicentre Phase II Study of XELOX with Bevacizumab in Late-stage Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancer: An ASCA Study. Jpn J Clin Oncol 2011; 41: 134-8.
  206. Krotov NF, Rasulov AE, Almardonov RB, Madiyarov BT, Chernishova TB, Oba K, Mamarajabov SE. Antireflux cervical esophagogastricoanastomosis in the surgery of esophageal cancer. Ann Cancer Res Ther 2010; 18: 59-64.
  207. Ueshima K, Yasuno S, Oba K, Fujimoto A, Mukoyama M, Ogihara T, Saruta T, Nakao K. Impact of Left Ventricular Hypertrophy on the Time-course of Renal Function in Hypertensive Patients: A Subanalysis of the CASE-J Trial. Circ J 2010; 74: 2132-8.
  208. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-analysis. JAMA 2010; 303: 1729-37.
  209. Zamani S, Farnia M, Torknejad A, Alaei BA, Gholizadeh M, Kasraee F, Kihara MO, Oba K, Kihara M. Patterns of drug use and HIV-related risk behaviors among incarcerated people in a prison in Iran. J Urban Health 2010; 87: 603-16.
  210. Yasuno S, Oba K, Ueshima K, Fujimoto A, Hirata M, Ogihara T, Saruta T, Nakao K. Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients? : A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Diabetes Care 2010; 33: 1122-7.
  211. Nakao K, Hirata M, Oba K, Yasuno S, Ueshima K, Fujimoto A, Ogihara T, Saruta T. Role of diabetes and obesity on outcomes of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res 2010; 33:600-6.
  212. Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama T, Azuma J, Ogihara T, Saruta T, Nakao K, for the CASE-J trial Group. Long-term Effects of Candesartan and Amlodipine on Cardiovascular Mortality and Morbidity in Japanese High-risk Hypertensive Patients: Rationale, Design, and Characteristics of Candesartan Antihypertensive Survival Evaluation in Japan Extension (CASE-J Ex). Contemp Clin Trials 2009; 30: 97-101.
  213. Ogihara T, Saruta T, Rakugi H, Fujimoto A, Ueshima K, Oba K, Takeda K, Higaki J, Nakao K, on behalf of the CASE-J Trial Group. Optimal Blood Pressure for Prevention of Cardiovascular Events in Hypertensive Patients with Complications: a subanalysis of the CASE-J trial. Hypertens Res 2009; 32: 248-54.
  214. Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: Update of a meta-analysis. Int J Clin Oncol 2009; 14:85-9.
  215. Yoshikawa T, Tsuburaya A, Hirabayashi N, Yoshida K, Nagata N, Kodera Y, Takahashi N, Oba K, Kimura M, Ishikura S, Miyashita Y, Sakamoto J. A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma. Cancer Chemother Pharmacol 2009; 64: 1071-7.
  216. Ueshima K, Yasuno S, Oba K, Fujimoto A, Ogihara T, Saruta T, Nakao K. Effects of Cardiac Complications on Cardiovascular Events in Japanese High-Risk Hypertensive Patients. Circ J 2009; 73: 1080-5.
  217. Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of immunochemotherapy with lentinan for patients with unresectable/recurrent gastric cancer: An individual-patient-based meta-analysis of randomized controlled clinical trials. Anticancer Res 2009; 29:2739-45.
  218. Yasuno S, Ueshima K , Oba K, Fujimoto A, Ogihara T, Saruta T, Nakao K. Clinical significance of left ventricular hypertrophy and changes of left ventricular mass in high-risk hypertensive patients: An analysis of CASE-J trial. J Hypertens 2009; 27: 1705-12.
  219. Nagata N, Kondo K, Shibata Y, Kato T, Okuyama Y, Ikenaga M, Tanemura H, Oba K, Sakamoto J, Mishima H. Multicenter Phase II Study of FOLFOX for Metastatic Colorectal Cancer in Japan: SWIFT-1 & 2 study. Hepatogastroenterology 2009 ;56: 1346-53.
  220. Kobayashi M, Tsuburaya A, Nagata N, Miyashita Y, Oba K, Sakamoto J. A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer 2006; 9: 114-9.

論文（和文）

  1. 福田武蔵, 坂巻顕太郎, 大庭幸治. 一般化ペアワイズ比較による生存時間解析. 日本統計学会誌 2023; 52(2): 319-354.
  2. 大庭幸治. 医療職のための学び直し : 研究デザインから論文報告までの生物統計学の道標(第20回)メタアナリシスの紹介. 厚生の指標 2022; 69 (11): 36-41.
  3. 大庭幸治. メタ解析の基礎と結果を解釈するときの留意点. （現代の臨床研究のための統計学2022）. 医学のあゆみ 2020;280(5):396-402.
  4. 大庭幸治. 相関と多変量解析．臨床雑誌整形外科 2020;71(6):559-564.
  5. 篠崎智大, 横田勲, 大庭幸治, 上妻佳代子, 坂巻顕太郎. イベント予測モデルの評価指標. 計量生物学 2020;41(1):1-35.
  6. 大庭幸治. メタアナリシスとプレシジョンメディシン．Precision medicine 2020;3 (13):26-9.
  7. 岩崎澄央、小山田玲子、渡邊翼、蓮池清美、中村澄人、山田武宏、大庭幸治、石黒信久．医療従事者における組換え沈降B 型肝炎ワクチン接種後のHBs 抗体持続期間に関する検討．環境感染誌 2018; 33(3): 117-122.
  8. 大庭幸治. ネットワークメタアナリシス：Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Coronary intervention 2017; 13(3): 56-62.
  9. 大庭幸治. 臨床研究のための統計学講座(第6回)論文の内容を吟味する時の統計学的なポイントを押さえよう. Rheumatology clinical research : journal of rheumatology clinical research 2016; 5(3): 213-216.
  10. 大庭幸治. 臨床研究のための統計学講座(第5回)応用的な解析方法について理解しよう : 繰り返し測定データの解析. Rheumatology clinical research : journal of rheumatology clinical research 2016; 5(2): 136-139.
  11. 大庭幸治. 臨床研究のための統計学講座(第4回)基本的な解析方法について理解しよう(2)重回帰分析やロジスティック回帰分析. Rheumatology clinical research : journal of rheumatology clinical research 2016; 5(1): 59-62.
  12. 大庭幸治. 臨床研究のための統計学講座(第3回)基本的な解析方法を理解しよう : 平均値の比較を中心に. Rheumatology clinical research : journal of rheumatology clinical research 2015; 4(3): 211-214.
  13. 大庭幸治. 臨床研究のための統計学講座(第2回)研究に必要な人数の計算方法を理解しよう : 統計的仮説検定とサンプルサイズ. Rheumatology clinical research : journal of rheumatology clinical research 2015; 4(2): 136-139.
  14. 大庭幸治. 臨床研究のための統計学講座(第1回)研究論文で目にする統計用語を理解しよう : 統計の基本用語からp値まで. Rheumatology clinical research : journal of rheumatology clinical research 2015; 4(1): 59-63.
  15. 大庭幸治. おさえておきたい基本の統計学知識 (特集 看護研究のイロハを学ぼう!). 循環器ナーシング : 基礎知識から最新トピックスまで!ハートナースとコメディカルのための循環器看護専門誌 2016; 6(12): 69-75.
  16. 大庭幸治. 非劣性試験のピットフォールPitfalls of non-inferiority trials. 循環器内科 2016; 79(3): 262-266.
  17. 大庭幸治. 胃がん臨床試験の個人データに基づくメタアナリシス. 胃がんperspective 2015;8:20-7.
  18. 出合美帆　大庭幸治　村元綾子　関口真理　佐々木由紀　橋本あきら　寺元剛　佐藤典宏. 北海道大学病院における自主臨床研究の臨床研究コーディネーター支援業務に関する アンケート調査. Jpn Pharmacol Ther 2014; 42:s154-9
  19. 佐久嶋研　大庭幸治　西村千佳子　佐藤典宏　梅木玲緒奈. 多職種協同による病院情報システム・電子カルテデータを臨床研究に活用するプロセス.情報処理学会デジタルプラクティス 2013; 4: 244-50.
  20. 保野慎治, 上嶋健治, 大庭幸治, 中尾葉子, 笠原正登, 藤本明, 宮脇尚志, 桝田出, 中尾一和. 慢性腎臓病発症予測因子の検討　人間ドックデータベースから見た生活習慣病の関わり. 健康管理事業団研究助成論文集 2011; XXVII: 19-27.
  21. 小林純子, 上嶋健治, 大江陽子, 福富まさ美, 井上房子, 高木真理子, 中本まり子, 藤堂祥子, 長谷部美代子, 山中真由美, 大庭幸治, 田中佐智子, 保野慎治, 藤本明, 中尾一和. CASE-J Ex試験への継続参加医師の背景因子について. 臨床評価 2011; 39: 407-12.
  22. 大庭幸治. メタ解析はオールマイティか. HeartView 2011; 15: 34-9.
  23. 上嶋健治, 大庭幸治, 田中佐智子, 保野慎治, 藤本明, 中尾一和. 日本人高血圧患者の心血管系イベント発症に及ぼすACE阻害薬およびARBの影響 – メタアナリシスからの検討 –. 循環器専門医　2011; 19: 25-33.
  24. 大江陽子, 上嶋健治, 大庭幸治, 福富まさ美, 井上房子, 高木真理子, 中本まり子, 小林純子, 保野慎治, 藤本明, 中尾一和. 臨床試験の症例登録は一部の参加医師により大部分がなされるのか？：CASE-J試験によるパレートの法則の検証. 臨床評価　2011; 38: 885-90.
  25. 田中司朗, 大庭幸治, 吉村健一, 手良向聡. 代替エンドポイントの評価のための統計的基準とその適用事例. 計量生物学会誌　2010; 31: 23-48.
  26. 坂本純一, 森田智視, 大庭幸治. DFSとOSの相関：大腸がん補助化学療法 – surrogate endpointの探索と留意点–. 腫瘍内科 2009; 4: 433-44.
  27. Hirata M, Oba K, Ueshima K, Nakao K. Obesity in CASE-J Study. 日本臨床 2009; 67:404-7.
  28. 大庭幸治. CASE-J －CASE-J Studyの軌跡－ CASE-Jの参加医師について－誰が参加し、なぜ参加したのか？－. 日本臨床 2008; 66: 28-32.
  29. 佐藤俊哉　森田智視　大庭幸治. CASE-J －CASE-J Studyの軌跡－ 医療統計家の役割. 日本臨床 2008; 66: 51-55.
  30. 上嶋健治　大庭幸治　保野慎治　藤本明　中尾一和. 臨床試験におけるEBM研究センターの役割：CASE-J試験を題材に. 循環器科 2008; 64: 266-70.
  31. 大橋靖雄　石塚直樹　大庭幸治　広崎真史　折笠秀樹. データマネージメントの難しさ‐今後のあり方（座談会）. 動脈硬化予防 2008; 6: 52-67.
  32. 平田雅一　上嶋健治　大庭幸治　中尾一和. CASE-J－肥満－ RASの新知見. Angiotensin Research 2007; 4:142-4.
  33. 上嶋健治　大庭幸治　保野慎治　藤本明　中尾一和. 臨床研究・基礎研究からみた循環器疾患予防の観点　CASE-J試験から学ぶもの. 日本循環器病予防学会誌2007; 42: 112-6.
  34. 上嶋健治　大庭幸治　中尾一和. 循環器研究のあたらしい潮流: CASE-J研究. 医学のあゆみ 2007; 220:531-7.
  35. 坂本純一　大庭幸治　小林道也　弓場健義. 腹膜播種の先進医療. 臨床外科 2006; 61: 769-774.
  36. 坂本純一　大庭幸治　松井隆則　小林道也. バイオセラピィに関するEBM. 　Biotherapy 2006; 20: 363-373.
  37. 坂本純一　大庭幸治. EBMにおけるランダム化比較試験. 天理医学紀要 2005; 8: 90-91.
  38. 大庭幸治　大橋靖雄. Regression Dilution. 動脈硬化予防2005; 4: 70-72.
  39. 松山裕　大庭幸治. Clinical Bioinformatics 統計解析の実際. Surgery Frontier 2004; 4: 82-89.
  40. 大津洋　大庭幸治. Clinical Bioinformatics臨床試験におけるデータマネジメント. Surgery Frontier 2004; 4: 90-93.

  1. Miyasato Y, Oba K, Masuda I, Mukoyama M. Investigation of the effect of visceral fat on the chronic kidney disease development and progression in medical checkup participants. 29th Scientific Meeting of the International Society of Hypertension (ISH), Kyoto, Japan, October 12-16, 2022.
  2. Fuyama K, Ogawa M, Mizusawa J, Oba K. Impact of correlations between prioritized outcomes on the net benefit and its estimate by generalized pairwise comparisons, WNAR/IMS, Online, 2022, June 10-15, 2022.
  3. Oba K, Paoletti X, Bang YJ, et al. Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials. Annual Meeting of ASCO2020, Online, June 4-6, 2020.
  4. Kozuma Ken, Kozuma Kayoko, Shinozaki T, Kashiwabara K, Oba K, Xience PMS Group, PROMUS Element/Element Plus PMS Group, Matsuyama Y. Predictors for angiographic edge restenosis of 2nd generation drug-eluting stents: Integrated angiographic analyses from the post-marketing surveillance studies of everolimus-eluting stents in Japan. ESC Congress 2018, Munich, Germany, August 25-29, 2018
  5. Kozuma Kayoko, Shinozaki T, Kozuma Ken, Kashiwabara K, Oba K, Aoki J, Awata M, Nanasato M, Shiode N, Tanabe K, Yamaguchi J, Kimura T, Matsuyama Y. Impact of residual stenosis on the angiographic edge restenosis of 2nd generation drug-eluting stents (A quantitative coronary angiography from the post-marketing surveillance studies of cobalt-chromium everolimus-eluting stent in Japan). EuroPCR 2018, Paris, France, May 22-25, 2018
  6. Nozaki T, Kashiwabara K, Shinozaki T, Oba K, Matsuyama Y, Ota E, Mori R. A network meta-analysis of prophylactic antibiotics for preventing post-cesarean endometritis. At: The 24th Cochrane Colloquium, Seoul, Korea. October 23–27, 2016.
  7. Yoshida K, Tsuburaya A, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Kurita A, Kojima H, Miyashita Y, Oba K, Buyse ME, Morita S, Sakamoto J. SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer. Oral Abstract Session, Gastrointestinal (Noncolorectal) Cancer 2013 ASCO Annual Meeting.
  8. Oba K, Burzykowski T. Validation of a surrogate endpoint by using the meta-analytic approach when the true endpoint is a rare binary-event. 34th　Annual Conference of the International Society for Clinical Biostatistics 25 – 29 August 2013 in Munich, Germany.

シンポジウム（国内）

  1. 大庭幸治．エビデンスを創出する臨床試験の必須要件 薬事戦略、データ品質管理、統計解析、研究支援組織．第38回環境感染学会総会, 横浜, 2023年7月20-22日.
  2. Oba K. Global Advanced/Adjuvant Stomach Tumor Research International Collaboration through Individual Patient based Data Meta-analysis: GASTRIC project, 日本臨床腫瘍学会, 京都, 2022年2月17-19日.
  3. 大庭幸治．メタアナリシス、ネットワークメタアナリシスの見方・読み方, 日本循環器学会関東甲信越地方会, オンライン, 2021年12月4日．
  4. 大庭幸治．癌臨床試験におけるセミパラメトリック加速モデルを用いた生存時間解析, 2021年度統計関連学会連合大会, 長崎, 2021年9月6－9日．
  5. 福田武蔵, 大庭幸治. 情報のある打ち切りを伴う生存時間データに対するNet Benefitの推定. 2020年度統計関連学会連合大会, 福井, 2020年9月8―12日.
  6. 大庭幸治.　 統計コンサルテーション, 2018年度計量生物学会年会, 東京, 2018年3月29-30日.
  7. 大庭幸治.　観察研究データを用いた予測モデルの構築, 2016年度ARO協議会第4回学術集会, 大阪, 2016年8月29-31日.
  8. 大庭幸治.　 統計的モニタリングで用いられる統計手法, 2016年度統計関連学会連合大会, 金沢, 2016年9月4-7日.
  9. 伊藤陽一　大庭幸治.　 アカデミアにおける統計家による研究支援体制（国内）, 2015年度統計関連学会連合大会, 岡山, 2015年9月6-9日.

  1. Oba K, Kuchiba A. Sample Size Calculations for Phase III Trials in Oncology. In: Halabi S, Michiels S (Eds.) Textbook of Clinical Trials in Oncology: A Statistical Perspective. CRC Press, FL, 2019
  2. Oba K, Paoletti X. Evaluation of Surrogate Endpoints using a Meta-Analysis Approach with Individual Patient Data: Summary of a Gastric Cancer Meta-Analysis Project. In: Matsui S, Crowley J(Eds.) Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, Singapore, 2017
  3. Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A,Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints in cancer clinical trials. In: Oncology Clinical Trials: Successful Design, Conduct and Analysis. Second Edition, Demos Medical Publishing, NY, 2017

著書等（和文）

  1. 大庭幸治：メタアナリシスの紹介. 生物統計学の道標 研究デザイン返ら論文報告までをより深く理解するための24講. 坂巻顕太郎　篠崎智大　監修　一般財団法人厚生労働統計協会　東京　2023
  2. 大庭幸治　他（訳者11名）: 臨床予測モデル ―開発・妥当性確認・更新の手引き―.　E.W. Steyerberg（著）　手良向 聡　大門 貴志　監訳　朝倉書店　東京　2023
  3. 大庭幸治: 臨床予測モデル．ヘルスデータサイエンス入門　―医療・健康データの活用を目指して―.　編集　手良向 聡　山本 景一　河野 健一 朝倉書店　東京　2023
  4. 大庭幸治: サロゲートエンドポイント．臨床試験の辞典　編集 丹後俊郎　松井茂之　2023
  5. 平田雅一　上嶋健治　大庭幸治　中尾一和：糖尿病に関する最近の治験：大規模臨床試験　分子糖尿病学の進歩　基礎から臨床まで　監修　矢崎義雄　清野進　渥美義仁　門脇孝　春日雅人　編　p124-128　金原出版　東京　2008
  6. 大庭　幸治　他　（訳者11名）：医学研究のための多変量解析一般回帰モデルからマルチレベル解析まで　木原雅子　木原正博　監訳　メディカルサイエンスインターナショナル　東京　2008
  7. 坂本純一　大庭幸治　小寺泰弘：胃癌の術後補助化学療法　別冊医学のあゆみ　消化器疾患ver.3 – state of arts I. 消化管 (食道･胃･腸)　編集　市倉隆　日比紀文　p585-587　医歯薬出版株式会社　東京　2006
  8. 坂本純一　松井隆則　大庭幸治：胃癌・大腸癌の術後補助化学療法　消化器がん化学療法2006　編集　市倉隆　p219-228　日本メディカルセンター　東京　2006

TOP